<DOC>
	<DOCNO>NCT00217503</DOCNO>
	<brief_summary>RATIONALE : Herpesvirus find cancer cell patient primary effusion lymphoma . Antiviral drug , zidovudine valganciclovir , may able act herpesvirus cancer cell help kill cancer cell . Bortezomib may help antiviral drug kill cancer cell . Draining effusion remove fluid build . Monoclonal antibody , bevacizumab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Bevacizumab may also stop growth cancer cell block blood flow cancer . Drugs use chemotherapy , cyclophosphamide , doxorubicin , etoposide , work different way stop growth cancer cell , either kill cell stop divide . Giving bortezomib together antiviral therapy follow effusion drainage , bevacizumab , combination chemotherapy may kill cancer cell . PURPOSE : This phase II trial study well give bortezomib together antiviral therapy follow effusion drainage , bevacizumab , combination chemotherapy work treat patient primary effusion lymphoma .</brief_summary>
	<brief_title>Bortezomib Antiviral Therapy Followed By Effusion Drainage , Bevacizumab , Combination Chemotherapy Treating Patients With Primary Effusion Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine complete response rate patient previously untreated primary effusion lymphoma treat effusion drainage bevacizumab combination chemotherapy comprise cyclophosphamide , doxorubicin , etoposide . Secondary - Determine overall survival , disease-free survival , progression-free survival patient treat regimen . - Determine toxicity regimen previously treat untreated patient . - Determine , preliminarily , biologic effect target oncolytic virotherapy comprise bortezomib , zidovudine , valganciclovir patient . OUTLINE : This 2-part , pilot study . Patients HIV-positive receive highly-active antiretroviral therapy study treatment . - Part 1 ( target oncolytic virotherapy ) * : Patients receive bortezomib IV 3-5 second day 1 , 4 , 8 , zidovudine IV 1 hour twice daily day 1-10 , oral valganciclovir ( ganciclovir IV ) twice daily day 1-14 . One day completion zidovudine , patient begin treatment part 2 . NOTE : *Part 1 treatment may omit patient acutely ill primary effusion lymphoma study entry AND 10- 14-day delay start part 2 treatment may pose hazard patient . - Part 2 - Effusion drainage : Patients undergo effusion drainage prior course bevacizumab* chemotherapy . The drainage tube may remain place allow continuous drainage effusion treatment bevacizumab* chemotherapy . - Bevacizumab* plus cyclophosphamide , doxorubicin , etoposide ( iCDE ) : Patients receive bevacizumab* IV 30-90 minute day 1 6 , cyclophosphamide , doxorubicin , etoposide IV continuously 96 hour begin day 1 continue day 5 , filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 6 continue day 19 blood count recover OR pegfilgrastim SC day 6 . NOTE : *Patients may receive iCDE without bevacizumab meet exclusion criterion receive bevacizumab . Treatment bevacizumab iCDE repeat every 21 day 4-8 course absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) receive 2 additional course beyond CR . After completion study treatment , patient follow monthly 6 month , every 2 month 6 month , every 3 month 1 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 15 patient accrue study within 2.5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Primary Effusion</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary effusion lymphoma ( PEL ) involve body cavity Kaposi 's sarcoma associatedherpesvirus Any anatomic site distribution involvement allow HIV infection allow Previously treat untreated disease No mass lesion brain ( patient receive bevacizumab study treatment ) PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 03* NOTE : *ECOG 4 allow due mechanical effect PEL correct effusion drainage result improved performance status ECOG 3 good Life expectancy Not specify Hematopoietic Absolute neutrophil count &gt; 1,000/mm^3 Platelet count &gt; 75,000/mm^3 No active bleeding coagulopathy ( patient receive bevacizumab study treatment ) Hepatic AST ALT &lt; 3 time upper limit normal ( ULN ) ( 6 time ULN due hyperalimentation ) Bilirubin &lt; 2.0 mg/dL OR Total bilirubin ≤ 4.5 mg/dL AND direct bilirubin &lt; 0.4 mg/dL ( patient Gilbert 's syndrome receiving proteaseinhibitor therapy ) Renal Creatinine ≤ 1.5 mg/dL OR Creatinine clearance &gt; 50 mL/min Cardiovascular Patients receive bevacizumab study treatment must meet following criterion : No deep venous arterial thrombosis within past 6 month No uncontrolled hypertension ( i.e. , systolic blood pressure [ BP ] &gt; 160 mm Hg diastolic BP &gt; 95 mm Hg ) No unstable angina No New York Heart Association class IIIV congestive heart failure No cardiac arrhythmia require medication No clinically significant peripheral artery disease No peripheral vascular disease ≥ grade 2 No prior myocardial infarction No transient ischemic attack cerebral vascular accident within past 6 month No clinically significant cardiovascular disease Neurologic Patients receive bevacizumab study treatment must meet following criterion : No uncontrolled seizure disorder No CNS bleed within past 6 month No substantial CNS disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy require treatment would preclude study treatment , include , limited , follow : Lifethreatening Kaposi 's sarcoma Nonresectable lung cancer Acute leukemia No grade IV organ dysfunction unrelated PEL No infection require chronic systemic therapy would preclude study treatment ( except HIV , hepatitis B , hepatitis C ) , include , limited , follow : Invasive aspergillosis Endorgan cytomegalovirus ( CMV ) CMV retinitis ( e.g. , ocular implant require systemic therapy ) allow controlled local therapy No condition circumstance would preclude study participation No gastrointestinal bleeding within past 6 month ( patient receive bevacizumab study treatment ) No pathological condition would confer high risk bleeding ( patient receive bevacizumab study treatment ) PRIOR CONCURRENT THERAPY : Biologic therapy No live virus vaccine ( e.g. , vaccinia rotavirus ) bacterial vaccine 3 month completion study treatment Chemotherapy No prior cumulative anthracycline dose &gt; 450 mg/m^2 ( unless cardiac ejection fraction normal ) Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No concurrent chronic daily aspirin ≥ 325 mg/day nonsteroidal medication interferes platelet function ( patient receive bevacizumab study treatment ) No concurrent therapeutic anticoagulation ( INR &gt; 1.5 ) unless patient fulldose warfarin ( patient receive bevacizumab study treatment ) Fulldose anticoagulant allow provide follow criterion meet : INR normal On stable dose warfarin lowmolecular weight heparin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
</DOC>